The Regenerve Protocol for Peripheral Neuropathy: Beyond Managing the Pain

The Regenerve protocol for peripheral neuropathy starts from a different premise than the standard script. Burning, tingling, and numbness are not the disease. They are the alarm. The goal of treatment is to repair the terrain the nerves live in, not just to mute the signal they are sending.

If you live with peripheral neuropathy, you already know that standard script. You get a prescription for gabapentin or pregabalin and a suggestion to control your blood sugar. Then you get a shrug when neither one gives your feet back to you. This article walks through the logic of that protocol and the science behind each stage. It also gives an honest account of what is established and what is less certain.

Why doesn’t nerve pain medication stop neuropathy from getting worse?

Most people are handed one of two drug types. One is the gabapentinoids (gabapentin, pregabalin). The other is certain antidepressants (duloxetine, amitriptyline). These drugs work by turning down pain signals in the nervous system. They are legitimate tools, and for many patients they take the edge off. But two facts are rarely explained at the pharmacy counter.

First, the benefit is often partial. Across the nerve-pain research, only a minority of patients get substantial (50% or greater) pain relief from any single drug taken by mouth. Many stop because of side effects like sleepiness, dizziness, weight gain, and mental fog. Second — and more important — none of these drugs touch the process that is damaging the nerve. They quiet the alarm while the fire keeps burning. That is why patients so often describe climbing to the top dose and still waking at 3 a.m. with their feet on fire.

The Regenerve premise is that lasting change requires addressing why the nerve is failing. Then you give it the conditions to recover.

Metabolic sovereignty: treating the terrain, not just the nerve

Dr. Gurpreet Singh Padda, MD, MBA, MHP, uses the phrase “metabolic sovereignty” to describe the core idea: your nerves cannot heal in a hostile environment. A nerve fiber is one of the most energy-hungry structures in the body. It must hold an electrical charge along its entire length. It must ship nutrients and mitochondria from the cell body out to the nerve endings. And it must keep repairing its insulating coat, the myelin. Starve it of oxygen, poison it with the byproducts of high blood sugar, or drain its energy supply, and it will misfire, pull back, and finally die back. That starts at the longest, most distant fibers, which is why symptoms begin in the toes and feet.

So before any regenerative step makes sense, the terrain has to be assessed and corrected: blood sugar and glycation, micronutrient status, circulation, inflammatory drivers, and mechanical contributors. This is the diagnostic backbone that a companion article — “The 11 Hidden Drivers Your Doctor Missed” — explores in depth. The protocol below assumes that this root-cause work is happening in parallel; the regenerative tools are not a substitute for it.

Stage one: can a capsaicin patch calm an overfiring nerve?

A damaged nerve can get stuck on high alert (chronically hyperexcitable). Then it fires pain even when there is no real threat. One way to interrupt that is to “defunctionalize” the overactive pain fibers at the skin level using high-concentration capsaicin.

The 8% capsaicin patch (marketed as Qutenza) is the most evidence-backed piece of this stage. It works on the TRPV1 receptor — the same receptor that makes chili peppers feel hot. That receptor sits on the small pain-sensing C-fibers in the skin. A single controlled application first overstimulates those endings. It then reversibly “switches off” those endings, cutting their pain signaling for weeks to months. This is not folk medicine. The U.S. FDA approved the 8% capsaicin patch for postherpetic neuralgia in 2009. After the pivotal STEP trial led by Dr. David Simpson, it approved it for painful diabetic peripheral neuropathy of the feet in 2020. In the controlled data, one 30-minute treatment led to modest but statistically significant drops in daily pain. The main side effect was temporary burning where it was applied. And — importantly — patients did not lose any ability to sense sharp, warm, cold, or vibration stimuli. A separate 52-week safety study (PACE) backed repeated treatment with no harm to function and no neurological (nerve) harm.

An honest caveat belongs here, because this is where marketing often overreaches. The established benefit of capsaicin is pain relief, not proven nerve regrowth. Can repeated capsaicin treatment help damaged nerve fibers actually regenerate? That is a real science question now under formal study. One example is a randomized disease-modification trial out of Cambridge. It is not a settled fact. Regenerve uses capsaicin to open a window. In it, there is less pain and less overactivity in the pain-sensing nerves (nociceptors). In that window, the repair-focused steps have room to work.

Stage two: can PRP or bone marrow concentrate support nerve repair?

Once the fire is calmer and the terrain is being corrected, the protocol turns to helping the tissue rebuild. This is where orthobiologics come in. These are biological materials meant to deliver growth factors and signaling molecules to injured tissue. In the Regenerve protocol they include platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC). Both come from the patient’s own blood or marrow.

The reasoning rests on real biology. Platelets are packed with growth factors. They include nerve growth factor and brain-derived neurotrophic factor. They also include vascular endothelial growth factor and platelet-derived growth factor. They direct healing and angiogenesis (growth of new blood vessels). In laboratory and animal models, they also direct peripheral nerve regeneration. BMAC also supplies a group of mesenchymal cells that can modulate (adjust) inflammation.

Here honesty is essential, and Regenerve’s material is careful about it. PRP and BMAC for peripheral nerve repair are offered as part of an individualized plan. The strongest evidence so far comes from preclinical models and small clinical series, not large randomized trials. Told honestly, they are a treatment made from the patient’s own body and based on how tissue heals. They show encouraging early signals, and the evidence is incomplete. That is exactly why they belong in a doctor-directed plan built for each person, with realistic expectations. They are not a one-size-fits-all promise.

Stage three: why do damaged nerves need working mitochondria?

Even a nerve that is whole cannot work if its mitochondria are failing. Mitochondria are the power plants inside each cell. Chronic hyperglycemia (long-term high blood sugar), toxins, and low nutrients all end in the same place: mitochondria that fail (mitochondrial dysfunction). Dr. Michael Brownlee’s landmark work found one common thread behind the tissue damage of diabetes. It is overproduction of mitochondrial superoxide, a harmful form of oxygen. Repairing the wiring without restoring the power supply leaves the job half done.

So the protocol includes mitochondrial support. At one end is well-established replacement of the helper nutrients (cofactors) nerves depend on. These include the B vitamins, alpha-lipoic acid, and CoQ10. At the other end are more advanced, targeted agents. SS-31 (elamipretide) is a mitochondria-targeted peptide. It is designed to steady cardiolipin, a fat in the inner mitochondrial membrane, and to improve energy production. It is a real compound under active study. This layer of support mixes proven nutrition science with newer targeted tools, chosen case by case.

Why sequence matters

The order is deliberate. Correcting the terrain first means the body is no longer actively re-injuring the nerve. Calming the overfiring pain fibers next opens a period of less pain and less chaos in the pain-sensing nerves. Repair signals and restored mitochondrial energy come last. They give the nerve both the instructions and the fuel to recover during that window. Reverse the order — try to “regenerate” a nerve that is still being starved and glycated every day — and you are building on sand.

How long does peripheral neuropathy treatment take to work?

Peripheral nerves repair slowly, about a millimeter a day at best. So this is a months-long process measured in gradual change, not an overnight fix. A realistic plan begins with evaluation and testing to map which drivers are active. It sets expectations honestly and adjusts over time based on response. Some patients see meaningful improvement. Results vary by person and by how advanced the nerve loss is at the start. The earlier the terrain is corrected, the more nerve there is to save.

Frequently asked questions

Key takeaways

• Standard drugs mute the pain signal but do not repair the nerve. Partial relief and side effects are common.
• The Regenerve protocol treats the terrain first. Then it calms overfiring nerves. Then it supports structural and mitochondrial repair.
• The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet. It gives real, if modest, pain relief. Nerve-regrowth claims are still under study.
• Orthobiologics (PRP, BMAC) and mitochondrial peptides (SS-31) make sense in biology. They belong in a plan built for each person (an individualized plan).
• Nerve repair is slow. Acting early saves more function.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication or treatment without consulting your physician. Ready to start? Take the free Nerve Damage Score or call (314) 886-5739 or text (314) 886-5902.

References

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
2. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
3. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for neuropathic pain associated with diabetic peripheral neuropathy of the feet. 2020.
4. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
5. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
6. Sánchez M, et al. Platelet-rich plasma and peripheral nerve regeneration (review of preclinical and early clinical evidence).
7. Szeto HH. First-in-class cardiolipin-protective compound (SS-31/elamipretide) as a therapeutic agent for mitochondrial dysfunction. Br J Pharmacol. 2014.